What commentary contributes

Much of the most-cited material in this field is argument rather than new data. Its main contribution has been scrutiny of how evidence is graded and used. The Endocrine Society's 2017 guideline rated the evidence behind every adolescent recommendation as low or very low yet still made some strong recommendations (Hembree et al., 2017), a gap a BMJ investigation examined with guideline-methods experts (Block, 2023). WPATH's eighth Standards of Care state that a systematic review for adolescents was "not possible" and grade no evidence (Coleman et al., 2022). Re-analyses have also narrowed headline claims: a journal correction found "no advantage of surgery" when 1,018 surgical patients in a Swedish registry study were compared with 1,018 similar patients (Society for Evidence-Based Gender Medicine, 2020), and individual scans from 24 English adolescents on puberty blockers showed about a third with abnormally low hip bone density after two years (Biggs, 2021). A recurring argument is that detransition and regret rates are unknown rather than low: published times to regret run from about 3 to over 10 years, and no study in a 2021 surgery-regret review followed at least 85% of patients for eight years (Cohn, 2023), while only about a quarter of surveyed detransitioners told their clinicians (Irwig, 2022).

Commentary has also supplied frameworks: a distinction between "core" and "non-core" detransition (Expósito-Campos, 2021), calls for follow-up of at least 5 to 10 years (MacKinnon et al., 2023), and an exploratory therapy model (Spiliadis, 2019). Pieces cut in different directions: one bioethicist argues serious treatments for minors need evidence of health benefit, not patient wishes alone (Gorin, 2024), while another essay likens exploratory therapy to conversion practices and cites a high detransition estimate of about 3% (Ashley, 2023).

Limits of the evidence

By design these papers add no new data, rarely use a systematic search, and select sources to fit an argument. Many authors have declared stakes, including funding from advocacy groups, think-tank affiliations, clinic roles and campaigning on either side, and some pieces received light review, one accepted nine days after submission (Wright et al., 2026). Many lean on the same few primary sources, such as one military pharmacy dataset and self-selected detransitioner surveys. Their claims are hypotheses and critiques for primary research to test.